Vesicle formation by the COPI complex has been a model system to understand how coat proteins act in vesicular transport 1, 2 , largely because a vesicle reconstitution system has been established that allows detailed mechanistic studies 5 . Early studies identified coatomer as the core component of the coat 6 and ARF1 (ADP ribosylation factor 1) as the small GTPase regulating this coat complex 7 . The GTPase-activating protein (GAP) that deactivates ARF1 was subsequently identified as ARFGAP1 (ref. 8) , which was also found to act as an ARF effector by being a coat component 9, 10 . BARS (Brefeldin-A ADP-ribosylated substrate) has also been identified to act in COPI vesicle formation, having a critical role at the fission stage 11 . Membrane fission by BARS was initially attributed to a LPAAT activity that converts lysophosphatidic acid to phosphatidic acid 12 . However, this activity was subsequently shown to be associated with, rather than intrinsic to, BARS (ref. 13) . In recent years, BARS has been found to possess an intrinsic ability to deform membranes, which requires the presence of phosphatidic acid as a critical lipid 14 . Moreover, the late stage of COPI vesicle fission was found to require phosphatidic acid generated by phospholipase D type 2 (PLD2; ref. 14) . Notably, CI-976, a pharmacologic compound that targets LPAAT activity 15 , has previously been shown to inhibit COPI vesicle formation 11 . Thus, we sought to delineate how both phosphatidic-acid-generating enzymatic activities (LPAAT and PLD) could be acting in COPI vesicle formation.
When CI-976 was added to the COPI reconstitution system, we found by electron microscopy that the Golgi membrane contained buds during early incubation, and then tubules of progressively longer length on longer incubation (Fig. 1a) . This sequence of events was further confirmed by electron microscopy morphometry coupled to kinetic analysis (Fig. 1b) . Thus, rather than simply arresting COPI vesicle formation at the stage of bud formation, inhibiting LPAAT activity by CI-976 had the additional effect of diverting COPI buds towards tubule formation.
In recent years, a family of transmembrane proteins has been shown to possess LPAAT activity 16 , with LPAATγ having been found to regulate Golgi structure and transport 17 . However, this role remains to be better defined. By confocal microscopy, we found that LPAATγ had a distribution at the Golgi that co-localized with coatomer (Supplementary Fig. S1a ). To determine whether LPAATγ acted in COPI transport, we initially tracked the redistribution of a COPI cargo (VSVG-KDELR, vesicular stomatitis virus G protein fused with the Lys-Asp-Glu-Leu receptor) from the Golgi to the endoplasmic reticulum, as previously described 11, 14, 18 . In cells treated with short interfering RNA (siRNA) against AGPAT3, which encodes LPAAT-γ, this redistribution was inhibited. This inhibition could be rescued by an siRNA-resistant form of the wild-type AGPAT3, which was abrogated by a catalytic-dead mutation (Fig. 1c) . Revisiting the COPI reconstitution system, we found that vesicle formation was inhibited on the addition of an anti-LPAATγ antibody (Fig. 1d) . Examining the Golgi membrane in this setting, we again observed buds followed by tubules of progressively longer lengths ( Supplementary Fig. S1b ). Thus, we concluded that CI-976 probably targeted LPAATγ on the Golgi membrane to inhibit COPI vesicle formation and promote tubule formation. Quantification of Golgi tubules on the addition of CI-976 to the reconstitution system. Golgi tubules within particular lengths, as indicated, were quantified, and then grouped and expressed as a fraction of the total. The mean from three experiments with standard error is shown. (c) COPI-dependent retrograde transport, as tracked by the redistribution of VSVG-KDELR from the Golgi to the endoplasmic reticulum (ER), requires the catalytic activity of LPAATγ. HeLa cells were left untreated (None), or were treated with siRNA against AGPAT3 or against an irrelevant sequence (encoded by GFP ), and also transfected with VSVG-KDELR. For rescue experiments, cells were also transfected with an siRNA-resistant form of wild-type (WT) LPAATγ or a catalytic-dead point mutant (H96A). The endoplasmic reticulum pattern for the chimaeric KDELR was then quantified. The mean from three experiments with standard error is shown. (d) An anti-LPAATγ antibody inhibits COPI vesicle formation. Antibodies as indicated were incubated with Golgi membrane, and then added to the COPI reconstitution system. The release of β-COP from Golgi membranes after the second-stage incubation was then quantified. The mean from three experiments with standard error is shown.
We next considered that phospholipase A2 (PLA2) activity should oppose the enzymatic activity of LPAAT, by converting phosphatidic acid to lysophosphatidic acid 19 . Pharmacologic inhibitors have been developed, with MAFP (methyl arachidonyl fluorophosphonate) targeting cytosolic forms of PLA2, and BEL (bromoenol lactone) preferentially targeting a subfamily within this group (known as calcium-independent PLA2; ref. 19) . MAFP promoted COPI vesicle formation, but BEL did not ( Supplementary  Fig. S2a ). These results were further confirmed by dose-response analysis ( Supplementary Fig. S2b ). Thus, we concluded that a calcium-dependent Group IV cPLA2 was acting to inhibit COPI vesicle formation.
A member of this group, cPLA2α, has been found to have a Golgi distribution 20 . We found that this Golgi pool co-localized with coatomer ( Supplementary Fig. S2c ). We also found that the overexpression of cPLA2α inhibited retrograde COPI transport in vivo, which was abrogated by a catalytic-dead mutation (Fig. 2a) . Revisiting the reconstitution system, we found that the addition of recombinant cPLA2α inhibited COPI vesicle formation (Fig. 2b) . Calcium was needed for the recruitment of recombinant cPLA2α to the Golgi membrane, which could be reversed by BAPTA [1,2-bis(o-aminophenoxy) ethane-N ,N ,N ,N -tetraacetic acid], a calcium chelating agent (Fig. 2c) . Calcium also promoted the ability of cPLA2α to inhibit vesicle formation, which was again reversed by the addition of BAPTA (Fig. 2d) .
To examine the role of endogenous cPLA2α in COPI vesicle formation, we found that the Golgi pool could be reduced by washing Golgi membrane more stringently ( Supplementary Fig. S2d ). This reduction prevented the ability of MAFP to enhance vesicle formation ( Supplementary Fig. S2e ). Consistent with this finding, the addition of an antibody against cPLA2α to the reconstitution system also enhanced vesicle formation (Fig. 2e) . We also found that the addition of recombinant cPLA2α to the reconstitution system induced tubule formation (Fig. 2f) . Thus, we concluded that cPLA2α opposed the role of LPAATγ in modulating vesicle versus tubule formation. cPLA2α requires calcium. The reconstitution system was carried out, with the second-stage incubation containing components as indicated. BARS was added in all conditions. The mean from three experiments with standard error is shown. (e) An anti-cPLA2α antibody added to Golgi membrane promotes COPI vesicle formation. The reconstitution system was carried out using Golgi membrane washed with 0.5 M KCl. ARFGAP1 was added at a reduced level, so that potential enhancement in COPI vesicle formation above the basal level could be more readily detected. The fractional release of β-COP from Golgi membrane after the second-stage incubation was normalized to the control (no antibody added). The mean from three experiments with standard error is shown. (f) Quantification of Golgi tubules seen on adding recombinant cPLA2α to the reconstitution system. The reconstitution system was carried out, with the second-stage incubation containing ARFGAP1, BARS and recombinant cPLA2α. Subsequently, Golgi tubules within particular lengths, as indicated, were quantified, and then grouped and expressed as a fraction of the total. The mean from three experiments with standard error is shown.
We also sought to confirm more directly that these two enzymatic activities regulated the level of phosphatidic acid on Golgi membrane. Phosphatidic acid species were detected on the Golgi membrane using mass spectrometry ( Supplementary Fig. S3a,b) . The level of phosphatidic acid decreased on the addition of CI-976 ( Fig. 3a and Supplementary Fig. S3c ) or recombinant cPLA2α ( Fig. 3b and Supplementary Fig. S3c ). The diacylglycerol level was also decreased by adding CI-976 ( Supplementary Fig. S3d ,e), which could be attributed to the Golgi possessing a phosphatidic acid phosphatase activity 21 . As a control, the levels of other lipids, such as phosphatidylcholine, phosphatidylserine and sphingomyelin, were unchanged by either perturbation (Fig. 3a,b) .
We next sought to elucidate the mechanistic relationship between the COPI complex and the two lipid enzymatic activities. When an anti-coatomer antibody was added to the reconstitution system, we found that COPI vesicle formation was blocked (Fig. 3c) . Electron microscopy analysis revealed that the antibody inhibited the initial stage of bud formation, as the Golgi membrane was devoid of protrusive structures (Fig. 3d) . We also found that the various ways of promoting tubule formation, either by inhibiting LPAATγ activity or by promoting cPLA2α activity, could not overcome the inhibitory effect of the anti-coatomer antibody (Fig. 3e) . Thus, we concluded that the COPI complex acted initially in promoting bud formation from the Golgi membrane, and then the opposing enzymatic activities of LPAATγ and cPLA2α dictated whether such buds became vesicles or tubules (Fig. 3f) .
As further support, we next replaced purified protein components in the reconstitution system with cytosol. Tubule formation could also be observed by either inhibiting LPAAT activity using CI-976 antibody. The antibody was added to the reconstitution system followed by examination of Golgi membrane using electron microscopy. Representative images are shown; scale bar, 50 nm. (e) Tubule formation is inhibited by the anti-coatomer antibody. The reconstitution system was carried out with additional components as indicated. The number of tubules (>100 nm in length) was then quantified by electron microscopy, and expressed as a percentage of all protrusions seen on Golgi membrane. The mean from three experiments with standard error is shown. (f) Summary of how key determinants act in COPI vesicle versus tubule formation. The COPI complex initially drives the formation of buds from Golgi membrane. Subsequently, cPLA2α activity promotes elongation of these buds to become tubules. In contrast, LPAATγ activity commits these buds towards vesicle formation by promoting the early stage of fission, which initiates the constriction of the bud neck, followed by PLD2 activity that completes vesicle fission.
or enhancing cPLA2 activity by adding the recombinant protein ( Supplementary Fig. S4a ). Parallel to these findings, vesicle formation was reduced when LPAAT activity was inhibited or when cPLA2α activity was promoted ( Supplementary Fig. S4b ). We also found that the depletion of coatomer reduced the ability of cytosol to support either tubule ( Supplementary Fig. S4a ) or vesicle ( Supplementary  Fig. S4b ) formation. We next sought to elucidate physiologic role(s) of COPI tubules. Golgi tubules have recently been shown to be promoted by cPLA2α activity, and characterized to act in anterograde intra-Golgi transport and Golgi ribbon formation 22 . Thus, we examined whether COPI was also critical for these two events. To avoid a complete disruption of Golgi stacking due to prolonged inhibition of coatomer 23 , we microinjected an anti-coatomer antibody into cells. This treatment transformed a Golgi marker from a ribbon-like pattern to a dispersed punctate pattern, as assessed by immunofluorescence microscopy (Fig. 4a) . Electron microscopy revealed that this transformation represented Golgi ribbons being converted into mini-stacks ( Fig. 4b and Supplementary Fig. S4c ). The number of Golgi vesicles also decreased (Fig. 4c) . This effect was not simply a consequence of Golgi transformation, because the conversion of Golgi ribbons into mini-stacks by a different mechanism (using nocodazole to disrupt microtubules) did not decrease the number of Golgi vesicles significantly ( Supplementary Fig. S4d ). We next assessed anterograde intra-Golgi transport by tracking the transit of VSVG across the Golgi stacks. Cells microinjected with the anti-coatomer antibody showed delayed arrival of VSVG to the trans-Golgi network (TGN; Fig. 4d ). Thus, as the inhibition of coatomer led to similar effects on Golgi ribbon formation and anterograde intra-Golgi transport as previously observed for the inhibition of cPLA2α, we concluded that Golgi tubules found recently to be promoted by cPLA2α probably required the COPI complex for their initial generation. A possibility was that inhibition of anterograde intra-Golgi transport in the microinjected cells was an indirect effect of having inhibited retrograde COPI vesicular transport. To address this issue, we noted that PLD2 acts in late COPI vesicle fission 14 , when the fate of COPI buds should already have been determined in becoming vesicles. We initially confirmed this prediction, as the addition of an antibody against PLD2 did not affect COPI tubule formation ( Supplementary  Fig. S4e ). Subsequently, on microinjecting an anti-PLD2 antibody into cells, anterograde intra-Golgi transport of VSVG was also unaffected (Fig. 4e) . In contrast, this microinjection had previously been shown to inhibit retrograde COPI transport 14 . Thus, we concluded that the anti-coatomer antibody probably directly inhibited anterograde intra-Golgi transport.
We also noted that the deletion of either PLD1 (ref. 24) or PLD2 (ref. 25) in mice had not revealed marked changes in the early secretory system, which was in contrast to the effects of perturbing coatomer 23 . Thus, we sought to confirm that PLD2 acted in retrograde COPI vesicular transport by another approach, by pursuing acute pharmacologic inhibition. As assessed by the reconstitution system initially, we found that a PLD2 inhibitor 26 , but not a PLD1 inhibitor 27 , reduced vesicle formation ( Supplementary Fig. S5a ). Electron microscopy confirmed that the late stage of vesicle fission was inhibited (Supplementary Fig. S5b ). We also found that only the PLD2, but not the PLD1, inhibitor blocked retrograde COPI transport in vivo by tracking the fate of VSVG-KDELR ( Supplementary  Fig. S5c ). We next found that the PLD2 inhibitor had no significant effect on tubule formation, as assessed by the reconstitution system ( Supplementary Fig. S5d) . Moreover, the PLD2 inhibitor did not affect anterograde intra-Golgi transport in vivo by tracking the fate of VSVG ( Supplementary Fig. S5e ). Thus, similar to the effects of antibody microinjection, the use of pharmacologic inhibition also revealed that the acute targeting of PLD2 activity affected only retrograde COPI vesicular transport but not anterograde COPI tubular transport. Notably, this selective role of PLD2 also helped to explain why the deletion of PLD2 did not induce defects in the early secretory system as severe as those seen on the perturbation of coatomer, as PLD2 acted only in retrograde COPI transport whereas coatomer acted in bidirectional COPI transport. We next sought insight into how COPI tubules promoted anterograde intra-Golgi transport. Golgi membrane was collected from cells that expressed either VSVG (as the model anterograde cargo) or VSVG-KDELR (as the model retrograde cargo). On the reconstitution of either COPI vesicles or tubules from Golgi membrane, we found that VSVG-KDELR was selectively incorporated into COPI vesicles (Fig. 5a ). In contrast, both VSVG and VSVG-KDELR were detected in COPI tubules (Fig. 5b) . To determine why COPI tubules seemed to transport cargoes non-selectively, we pursued electron microscopy morphometry, which revealed that both VSVG (Fig. 5c ) and VSVG-KDELR (Fig. 5d) were diffusely distributed along tubular membrane. In contrast, coatomer was concentrated at the tip and base of tubules (Fig. 5e) . We also scrutinized the electron-dense coating on different membrane structures by electron microscopy, and found that COPI buds and vesicles exhibited more obvious coating than COPI tubules (Fig. 5f ). As confirmation, we assessed the relative density of COPI vesicles versus tubules using density gradients. COPI tubules were released from Golgi membrane by pipette-induced shearing, and as a control, reconstituted COPI vesicles were subjected to a similar treatment. Whereas COPI vesicles exhibited a density equivalent to 43% sucrose, as previously documented 9 , COPI tubules exhibited a lighter density (Fig. 5g) . Thus, when the results were taken together, we concluded that cargoes were transported non-selectively in COPI tubules, because the coat complex was not sufficiently concentrated on these membrane structures to allow a more selective mechanism of cargo sorting. Moreover, because anterograde cargoes should have a concentration gradient at the Golgi complex, which would be higher at the cis as compared with the trans side (as anterograde cargoes are derived from the endoplasmic reticulum), the elucidated mechanism of transport for COPI tubules could help drive anterograde transport through the Golgi stacks.
We have found that the COPI complex is critical for the initial generation of buds from Golgi membrane that can then become either vesicles or tubules. The fate of nascent buds depends on the relative activity of two opposing lipid enzymatic activities. LPAATγ promotes the early stage of fission to direct buds in becoming COPI vesicles. In contrast, cPLA2α, which promotes the converse enzymatic reaction, inhibits early COPI vesicle fission to divert buds in becoming tubules. Moreover, as we have found previously that PLD2 acts at the late stage of COPI vesicle fission 14 , the present finding that LPAATγ acts at the early stage of COPI vesicle fission uncovers the surprising complexity by which phosphatidic acid acts in the fission process (summarized in Fig. 3f ). Our present findings may also enable the resolution of an ongoing contentious debate regarding the role of COPI in intra-Golgi transport 28, 29 . Originally, COPI was proposed to form vesicles that act in anterograde transport across the Golgi stacks. In recent years, cisternal maturation has gained favour in explaining anterograde intra-Golgi transport, relegating COPI to act mainly in retrograde transport 28, 29 . Notably, in any of the models that have been considered thus far, COPI has been assumed to act in vesicular transport. In contrast, our finding that COPI also acts in tubular transport, and such carriers promote anterograde transport across the Golgi stacks, now offers a fresh reconciling explanation for how COPI acts in both directions of intra-Golgi transport. We further note that extensive characterization of different coat proteins thus far has revealed physiologic roles only in vesicle formation 1, 2 . Moreover, studies on model systems of tubular transport have not identified coat proteins to play a major role 3, 4 . As such, we have also revealed an unanticipated mechanistic relationship between vesicular and tubular transport. , BARS, Golgi membrane and cytosol has been described previously 9, 11 . Preparation of recombinant cPLA2 isoforms has also been described previously 30 . HeLa cells were cultured as previously described 11 .
METHODS

Methods
Plasmids and antibodies. VSVG and VSVG-KDELR in mammalian expression vectors have been described previously 11, 18 . Both contain a temperature-sensitive mutation of VSVG (ts-045). Human AGPAT3 complementary DNA was inserted into EcoR1 and EcoRV sites of the mammalian expression vector p3×Flag-CMV. A catalytic-dead mutant (H96A; ref. 31) was generated using the QuikChange Site-Directed-Mutagenesis Kit (Stratagene) and the paired oligonucleotides 5 -GCAGTCATCATCCTCAACGCCAACTTCGAGATCGACTTCC-3 and 5 -GGAAGTCGATCTCGAAGTTGGCGTTGAGGATGATGACTGC-3 . Human cPLA2α and the corresponding catalytic-dead point mutant were inserted into the HindIII and PstI sites of the mammalian expression vector pECFP(C3).
Mouse antibodies have been described previously, including anti-β-COP (M3A5 culture supernatant used at 1:3 dilution), anti-VSVG (BW8G65 culture supernatant, 1:10 dilution), anti-Myc (9E10 culture supernatant, 1:10 dilution) and anticoatomer (CM1A10 culture supernatant, 1:10 dilution) antibodies 9, 11, 18, 32 . Rabbit antibodies have also been described previously 9, 11, 14, 18, 22 , including anti-cPLA2α (used at 1:500 dilution), anti-mannosidase I (anti-ManI; 1:500 dilution), anti-ε-COP (1:500 dilution), anti-ζ-COP (1:500 dilution), anti-KDELR (1:500) and anti-PLD2 (1:1,000 dilution). An antibody against human LPAATγ was generated by injecting rabbits with the central domain (residues 78-300) as a recombinant protein, and used at 1:1,000 dilution. A rabbit anti-α-COP antibody (1:500 dilution) was obtained (gift from F. Wieland, Heidelberg University, Germany). Secondary antibodies that were obtained (Jackson ImmunoResearch) include cyanine 2 (Cy2)-or Cy3-conjugated donkey antibodies against mouse or rabbit IgG (both used at 1:200 dilution), and horseradish-peroxidase-conjugated donkey antibodies against mouse or rabbit IgG (both used at 1:20,000 dilution). Gold (10 nm diameter)-conjugated goat antibodies against rabbit IgG (used at 1:250 dilution) were also obtained (Sigma).
In vitro reconstitution system. The COPI reconstitution system was carried out as previously described 11 . Briefly, Golgi membrane (0.2 mg ml −1 ) was washed with 3 M KCl, and then incubated with ARF1 (6 µg ml −1 ) and coatomer (6 µg ml −1 ) for the first-stage incubation that reproduces the ARF-dependent recruitment of coatomer onto Golgi membrane. The Golgi membrane was re-isolated and then incubated with ARFGAP1 (2 µg ml −1 ) and BARS (2 µg ml −1 ) for the second stage that results in vesicle formation. Although PLD2 is also required for COPI vesicle formation 14 , it was not added to the reconstitution system, because an endogenous pool remained on Golgi membrane after washing with 3 M KCl (ref. 14). CI-976 was used at 20 µM. PLD inhibitors were used at 1 µM. For the initial characterization of PLA2 activity on Golgi membrane that involved pharmacologic inhibition, the membrane was washed with 0.5 M KCl to allow endogenous PLA2 activity to remain on Golgi membrane. Doses of BEL and MAFP used in these studies are indicated in the individual figures. Reconstitutions that added the recombinant forms of cPLA2 (0.6 µg ml −1 ) used Golgi membrane washed with 3 M KCl. For antibody blocking studies, Golgi membranes (100 µg) were also washed with 0.5 M KCl to retain an endogenous pool of the targeted protein, followed by antibody addition (5 µl).
To examine cargoes in COPI tubules versus vesicles, COS-1 cells were transiently transfected with either VSVG or VSVG-KDELR, followed by isolation of Golgi membrane from these cells. Cells that express VSVG-KDELR were incubated at the permissive temperature (32 • C), as this chimaera resides mostly at the Golgi at this temperature. In contrast, cells that express VSVG were shifted from the non-permissive temperature (39 • C) to the permissive temperature (32 • C) for 10 min to collect a synchronized pool of this chimaera at the Golgi.
Electron microscopy. Examination of Golgi membrane or reconstituted vesicles using the whole-mount technique has been described previously 9, 11 . Examination of cells after Epon-embedding followed by serial thin sectioning has also been described previously 33 . Quantification was carried out as described in the figure legends.
Transfections and siRNA and rescue. Transfection of DNA plasmids was carried out using FuGene6 (Roche). Transfection of siRNA was carried out using Oligofectamine (Invitrogen). The siRNA sequence used to target human AGPAT3 (5 -GAGACCAAGCACCGCGTTA-3 ) was obtained (Dharmacon). Rescue plasmids for wild-type and the catalytic-dead mutant of human AGPAT3 were generated by targeting this siRNA sequence using the QuikChange Site-Directed-Mutagenesis Kit (Stratagene) with paired oligonucleotides 5 -CGCTTCACGGAGACCAAGCATAGGGTTAGCATGGAGGTGGCG-3 and 5 -CGCCACCTCCATGCTAACCCTATGCTTGGTCTCCGTGAAGCG-3 .
In vivo transport assays. COPI retrograde transport as assessed by the redistribution of VSVG-KDELR has been described previously 11, 18 . Anterograde transport of VSVG has also been described previously 22, 34 . PLD inhibitors were added at 100 nM.
Microinjections. Microinjection of antibodies (1 mg ml −1 ) was carried out as previously described 34 .
Lipid analysis. Golgi lipids were measured using comparative mass spectrometry 35 . Briefly, Golgi membrane in assay buffer (25 mM HEPES at pH 7.2, 50 mM KCl, 2.5 mM Mg(OAc) 2 and 200 mM sucrose) was extracted 36 with 4 ml of CHCl 3 /CH 3 OH (2/1, volume ratio) and 2 ml of PBS-saturated CHCl 3 /CH 3 OH (2/1, volume ratio) successively. Organic phases were pooled and dried under vacuum (GeneVac). The remaining aqueous phase was acidified with cold acetic acid to pH 3-4 and extracted twice with 2 ml of cold PBS-saturated CHCl 3 /CH 3 OH (2/1, v/v). Organic phases were pooled and neutralized with cold 10% trietylamine in CHCl 3 /CH 3 OH (2/1, volume ratio). The neutralized organic phase was combined with initial extractions and dried under vacuum. Lipid detection was carried out using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) in the negative mode (Agilent 6520 Q-TOF mass spectrometer combined to an Agilent 1200 series HPLC system), essentially as previously described 35 . Briefly, chromatography was carried out using a silica column (100×2.1 mm dimension with a 5µ matrix). Solvent A was hexanes/isopropanol 1/1 (volume ratio), 0.02% NH 4 OH and 0.01% HCOOH and solvent B was hexanes/isopropanol/water 2/4/1 (volume ratios), 0.02% NH 4 OH and 0.01% HCOOH. The solvent gradient was (0.15 ml min −1 ): 0-8 min; 100% A, 8-13 min; 0-100% linear B, 13-18 min; 100% B and 18-23 min; 0-100% linear A, followed by a 10 min conditioning post-run (100% A). A volume of 20 µl of the dried Golgi membrane lipid extract resuspended in 50 µl of solvent A was injected per analysis. The different phosphatidic acid forms were detected in the Golgi lipidic extract at the same retention time (5.5 min) as a standard (C16, C18:1) with a mass accuracy of 1-5 ppm. The different diacylglycerol forms were detected at the same retention time (1.1-1.3 min) as a standard (C16, C18:1) with a mass accuracy of <1 ppm. The phosphatidic acid molecular species assignment was confirmed by collisional experiments carried out in the negative mode using a 25 V collision energy. Other lipid species were assigned on the basis of previously described polarity and on the accuracy of the detected m/z (1.2 ppm).
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Figure S1 The ability of MAFP to promote COPI vesicle formation is abrogated upon more stringent washing of Golgi membrane. The COPI reconstitution system was performed using washed Golgi membrane and concentration of MAFP as indicated. The second-stage incubation contained ARFGAP1 when using 0.5M KCl-washed Golgi membrane and both ARFGAP1 and BARS when using 3M KCl-washed Golgi membrane. The fractional release of β-COP from Golgi membrane after the second-stage incubation was normalized to control incubation (which contained vehicle only). The mean from three experiments with standard error is shown. ) . The level of Golgi-associated vesicles was then quantified. The mean from three experiments with standard error is shown. The student's t-test was performed for the two conditions, which showed no significant difference (P > 0.05). (e) COPI tubule formation still occurs upon acute inhibition of PLD2. The reconstitution system was performed. For the second stage incubation, recombinant cPLA2-α and anti-PLD2 antibody were added additionally. Golgi tubules within particular lengths, as indicated, were quantified, and then grouped and expressed as a fraction of total. The mean from three experiments with standard error is shown. 
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